Beyhun N Ercüment, Cilingiroğlu Nesrin, Sekerel Bülent E
Department of Public Health, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
Turk J Pediatr. 2007 Apr-Jun;49(2):179-88.
Bronchial asthma is one of the most common chronic diseases of childhood. In recent years a consistent increase in the prevalence, and concomitantly, in the social and economic impact of the disease, has been reported. In order to provide data for the cost of pediatric asthma and its determinants in Turkish children, a study was performed in a single outpatient clinic, which encompasses a questionnaire-guided interview and retrospective evaluation of the last year files. From the 183 patients enrolled, most were males (65.6%) and atopics (63.5%), with a disease severity of mild intermittent (67.7%). Mean annual total costs per patient was US $991.7 +/- 73.2 (median = 688.8) and the largest proportion of the direct costs was due to outpatient clinic costs (48.5%). Mean cost of any hospitalization per patient was US $955.5 +/- 16.5. In multivariate analysis, the disease severity, current use of preventive drugs and current use of emergency sevice and/or current hospitalization appeared to be the main determinants of direct costs. Adequate control of the disease plays a key role in decreasing the total direct costs of pediatric asthma although it increases the medication and outpatient costs.
支气管哮喘是儿童期最常见的慢性疾病之一。近年来,该病的患病率持续上升,其对社会和经济的影响也随之增加。为了提供土耳其儿童哮喘治疗费用及其决定因素的数据,在一家门诊诊所开展了一项研究,该研究包括问卷调查引导的访谈以及对去年病历的回顾性评估。在纳入研究的183例患者中,大多数为男性(65.6%)且患有特应性疾病(63.5%),疾病严重程度为轻度间歇性发作(67.7%)。每位患者的年平均总费用为991.7美元±73.2美元(中位数=688.8美元),直接费用的最大部分是门诊费用(48.5%)。每位患者的任何住院平均费用为955.5美元±16.5美元。在多变量分析中,疾病严重程度、预防性药物的当前使用情况以及急诊服务和/或当前住院的当前使用情况似乎是直接费用的主要决定因素。尽管疾病得到充分控制会增加药物和门诊费用,但对降低儿童哮喘的总直接费用起着关键作用。